Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma

Han Wu; Han Wu; Han Wu; Xin-Fei Xu; Jia-Qi Zhu; Jia-Qi Zhu; Ming-Da Wang; Chao Li; Lei Liang; Lei Liang; Lei Liang; Hao Xing; Meng-Chao Wu; Feng Shen; Dong-Sheng Huang; Dong-Sheng Huang; Tian Yang; Tian Yang; Tian Yang

doi:10.3389/fbioe.2021.695635

Frontiers in Bioengineering and Biotechnology (Oct 2021)

Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma

Han Wu,
Han Wu,
Han Wu,
Xin-Fei Xu,
Jia-Qi Zhu,
Jia-Qi Zhu,
Ming-Da Wang,
Chao Li,
Lei Liang,
Lei Liang,
Lei Liang,
Hao Xing,
Meng-Chao Wu,
Feng Shen,
Dong-Sheng Huang,
Dong-Sheng Huang,
Tian Yang,
Tian Yang,
Tian Yang

Affiliations

Han Wu: Department of Hepatobiliary, Pancreatic and Minimal Invasive Surgery, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou, China
Han Wu: The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou, China
Han Wu: Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China
Xin-Fei Xu: Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China
Jia-Qi Zhu: Department of Hepatobiliary, Pancreatic and Minimal Invasive Surgery, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou, China
Jia-Qi Zhu: The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou, China
Ming-Da Wang: Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China
Chao Li: Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China
Lei Liang: Department of Hepatobiliary, Pancreatic and Minimal Invasive Surgery, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou, China
Lei Liang: The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou, China
Lei Liang: School of Clinical Medicine, Hangzhou Medical College, Hangzhou, China
Hao Xing: Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China
Meng-Chao Wu: Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China
Feng Shen: Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China
Dong-Sheng Huang: The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou, China
Dong-Sheng Huang: School of Clinical Medicine, Hangzhou Medical College, Hangzhou, China
Tian Yang: Department of Hepatobiliary, Pancreatic and Minimal Invasive Surgery, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou, China
Tian Yang: The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou, China
Tian Yang: Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China

DOI: https://doi.org/10.3389/fbioe.2021.695635
Journal volume & issue: Vol. 9

Abstract

Read online

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide, which lacks effective inhibition of progression and metastasis in the advanced clinical stage. Mesoporous silica nanoparticle (MSN)–based cytotoxic or immunoregulatory drug–loading strategies have attracted widespread attention in the recent years. As a representative of mesoporous biomaterials, MSNs have good biological characteristics and immune activation potential and can cooperate with adjuvants against HCC. This review summarizes the possible future development of the field from the perspective of tumor immunity and aims to stimulate the exploration of the immune mechanism of MSN-based therapy. Through this point of view, we hope to develop new clinical immune drugs that can be applied to HCC clinical management in the future.

Published in Frontiers in Bioengineering and Biotechnology

ISSN: 2296-4185 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Technology: Chemical technology: Biotechnology
Website: http://www.frontiersin.org/bioengineering_and_biotechnology

About the journal

Abstract

Keywords